AXIS, INC. Patent applications |
Patent application number | Title | Published |
20130196980 | DIAGNOSTIC AGENT, DIAGNOSTIC METHOD AND THERAPEUTIC AGENT FOR FIBROMYALGIA - A diagnostic agent and a diagnostic method for appropriately diagnosing fibromyalgia of a specific type, and a therapeutic agent for the aforesaid type include a diagnostic agent for fibromyalgia relating to an anti-voltage-gated potassium channel complex antibody (anti-VGKC complex antibody), said diagnostic agent containing a reagent for detecting the anti-VGKC complex antibody; a diagnostic method using the diagnostic agent; and a therapeutic agent for fibromyalgia relating to the anti-VGKC complex antibody. A diagnostic agent for fibromyalgia relating to an antibody against a voltage-gated potassium channel complex includes a reagent for detecting the antibody against the voltage-gated potassium channel complex; and a therapeutic agent for fibromyalgia relating to an antibody against voltage-gated potassium channel contains an effective amount of an anticonvulsant drug (gabapentine or clonazepam) as the active ingredient. | 08-01-2013 |
20130108637 | THERAPEUTIC AGENT FOR FIBROMYALGIA CONTAINING ETANERCEPT | 05-02-2013 |
20130034563 | USE FOR PRODUCTION OF THERAPEUTIC AGENT OR PROPHYLACTIC AGENT FOR OSTEOARTHRITIS - Methods for treating or preventing diseases classified as any of grade 1 to 3 according to the ICRS classification of osteoarthritis, classified as grade 1 to 3 according to the Kellgren-Lawrence classification of osteoarthritis, or classified as grade 1 to 3 according to the Outerbridge classification of osteoarthritis, include administering to a subject in need thereof a therapeutically effective amount of treatment agents or preventive agents containing an anti-Fas IgM antibody as an active ingredient to alleviate osteoarthritis symptoms by inhibiting the production of cartilage matrix degrading enzymes and by increasing the production of cartilage matrix. | 02-07-2013 |
20130011416 | INJECTABLE SOLUTION CONTAINING THERAPEUTIC AGENT FOR OSTEOARTHRITIS - Injections for treating and preventing diseases classified as any of grade 1 to 3 according to the ICRS classification of osteoarthritis, diseases classified as any of grade 1 to 3 according to the Kellgren-Lawrence classification of osteoarthritis or diseases classified as any of grade 1 to 3 according to the Outerbridge classification of osteoarthritis contain anti-Fas IgM antibody as an active ingredient and a pharmaceutically acceptable carrier to alleviate osteoarthritis symptoms by inhibiting the production of cartilage matrix degrading enzymes and by increasing the production of cartilage matrix. | 01-10-2013 |
20130011407 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OR PREVENTION OF OSTEOARTHRITIS, AND METHOD OF PRODUCTION THEREFOR - Pharmaceutical compositions for treating or preventing diseases classified as any of grade 1 to 3 according to the ICRS classification of osteoarthritis, classified as any of grade 1 to 3 according to the Kellgren-Lawrence classification of osteoarthritis or classified as any of grade 1 to 3 according to the Outerbridge classification of osteoarthritis and methods of manufacturing same contain anti-Fas IgM antibody as an active ingredient and a pharmaceutically acceptable carrier with acidity of pharmaceutical compositions ranging from pH 4 to pH 9 to alleviate osteoarthritis symptoms by inhibiting the production of cartilage matrix degrading enzymes and by increasing the production of cartilage matrix. | 01-10-2013 |
20110217387 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF FIBROMYALGIA - A pharmaceutical composition for the treatment of fibromyalgia, which includes pilocarpine or a pharmacologically acceptable salt thereof. The pharmaceutical composition can be used as a novel therapeutic agent for fibromyalgia. | 09-08-2011 |
20110182915 | THERAPEUTIC AGENT OR PREVENTIVE AGENT FOR OSTEOARTHRITIS - A method for treatment of disease classified as any of grade 1 to 3 according to the ICRS classification of osteoarthritis, any of grade 1 to 3 according to the Kellgren-Lawrence classification of osteoarthritis, or any of grade 1 to 3 according to the Outerbridge classification of osteoarthritis, the method includes a step of administrating an agent containing an anti-Fas IgM antibody as an active ingredient. | 07-28-2011 |